Endocrinology Video Recap—January 27, 2026

LucidQuest

5 minutes ago

This biweekly Endocrinology video recap covers regulatory actions, clinical research, data releases, and market dynamics across key markets.

🎯 Watch Our Video Summary Capturing Endocrinology News from the Last Two Weeks

Dive deeper

🗓️ Explore weekly details and sources

Week 13–19 January 2026
Week 20 –26 January 2026

📚 See the full Endocrinology archive on our research hub pag

Transcript

Welcome to the latest edition of Endocrinology updates, covering breakthroughs in the past two weeks. Brought to you by LucidQuest.

In Europe, the Commission approved Teizeild, also known as teplizumab, to delay stage 3 type 1 diabetes in stage 2 patients aged 8 years and older, supported by the TN-10 Phase 2 study. Safety includes transient lymphopenia and rash, consistent with prior data.
This is the first disease-modifying therapy for type 1 diabetes in the EU, which could shift clinical focus toward earlier stage-2 identification and expand screening programs in primary and specialty care.

In Korea, Mounjaro is reshaping the obesity prescription mix. HIRA-cited data indicate that by November, prescriptions for Mounjaro exceeded Wegovy, while the overall GLP-1 market continued to expand. The inflection favors tirzepatide in early adoption cycles, which may influence prescriber choice, dosing pathways, and payer reviews as comparative effectiveness and outcomes data mature.

From Japan, the Institute of Science Tokyo introduced DiaCardia, an AI model that identifies prediabetes using ECG alone, including single-lead inputs suitable for wearables. The model was trained and validated on health-check datasets and reported robust internal performance with external generalizability.
If replicated across diverse populations, ECG-only screening could extend reach beyond clinic labs, supporting earlier risk stratification and remote monitoring, though real-world impact will depend on study design and control for confounding.

A multicohort analysis reported in Nature Medicine linked 235 metabolites with incident type 2 diabetes and derived a 44-metabolite panel that improved prediction beyond standard risk scores. Diet and lifestyle correlated with metabolite patterns.These signatures may enable earlier, more precise prevention, informing personalized counseling and payer discussions, while reminding stakeholders that observational designs require careful interpretation.

Media coverage highlighted the DiaCardia finding that prediabetes can be screened using ECG data alone without blood tests. Reports reiterated internal Auroc and external validation claims from the academic sources.Broader awareness can accelerate pilot programs and funding, yet decisions should anchor on peer-reviewed endpoints, calibration performance, and prospective validation before scale-up.

Merck Healthcare Korea updated the Gonal-f Pen to a 31-gauge, 8-millimeter short needle, aiming to reduce injection burden without changing administration steps.A smaller, thinner needle can lower perceived pain and improve adherence during repeated self-injections, which may support timely cycles and better patient experience in infertility care.

In the United States, Hikma launched two denosumab biosimilars, Enoby and Xtrenbo, referencing Prolia and Xgeva under a 2021 agreement with Gedeon Richter. Dosing and presentations mirror the references, with safety considerations that include severe hypocalcemia risk, osteonecrosis of the jaw, and atypical femoral fractures. Biosimilar entry can ease budget impact in osteoporosis and oncology supportive care, potentially broadening access while maintaining established risk management protocols.

A study from Thailand associated type 2 diabetes with higher osteoporosis prevalence compared with non-diabetic peers, examining bone density with modifiers such as age, sex, and disease duration, though exact figures were not stated.The signal supports integrated metabolic-bone assessments in diabetes clinics, while underscoring the need for standardized definitions, fracture outcomes, and longitudinal follow-up to guide coverage and care pathways.

Stay ahead in endocrinology research! Like, share, and subscribe for weekly updates. Visit LQventures.com or email us at info@LQventures.com for expert healthcare consulting. See you next time.

Why it matters

Disease-modifying T1D approval in the EU may shift screening toward stage-2 identification.
GLP-1 market dynamics in Korea highlight rapid class growth and payer pressure on obesity care.
Noninvasive and at-home risk tools for prediabetes could broaden reach beyond clinic labs.
Metabolomic signatures may enable earlier, more precise prevention in T2D.
Biosimilar denosumab entry can ease budget impact in osteoporosis and oncology supportive care.

🗓️ Explore weekly details and sources

Week 13–19 January 2026
Week 20 –26 January 2026

📚 See the full Endocrinology archive on our research hub pag

FAQ

What did the EU approve for type 1 diabetes, and for whom?

The EU approved Teizeild (teplizumab) to delay progression to stage 3 type 1 diabetes in stage 2 patients aged eight years and older, based on evidence from the TN-10 Phase 2 clinical trial [1].

Did Mounjaro overtake Wegovy in Korea?

Yes. According to the report, HIRA data show that Mounjaro recorded higher prescription volumes than Wegovy in November, just four months after its launch, within the context of rapid overall growth of the GLP-1 market in Korea [2].

What is DiaCardia, and who developed it?

DiaCardia is an artificial intelligence model developed by the Institute of Science Tokyo that can identify prediabetes using electrocardiogram data alone, including single-lead ECG signals suitable for wearable devices [3][5].

What is the metabolomic signature for T2D risk?

A Nature Medicine study identified two hundred thirty-five metabolites associated with type 2 diabetes risk and developed a forty-four–metabolite panel that significantly improved prediction of incident type 2 diabetes beyond traditional clinical risk scores [4].

What changed with the Gonal-f Pen in Korea?

Merck Healthcare Korea introduced a new 31G, eight-millimeter short needle for the Gonal-f Pen, designed to reduce injection discomfort while keeping the administration process unchanged [6].

Which denosumab biosimilars launched, and where?

Hikma launched two denosumab biosimilars, Enoby and Xtrenbo, in the United States. These products reference Prolia and Xgeva, are manufactured by Gedeon Richter, and are commercialized by Hikma [7].

Entities / Keywords

Sanofi; Teizeild; teplizumab; TN-10; type 1 diabetes; Eli Lilly; Mounjaro; tirzepatide; Novo Nordisk; Wegovy; semaglutide; HIRA; Institute of Science Tokyo; DiaCardia; ECG; prediabetes; LightGBM; Nature Medicine; metabolomics; T2D risk signature; Merck Healthcare Korea; Gonal-f; r-hFSH; infertility; Hikma; Gedeon Richter; denosumab-qbde; Prolia; Xgeva; osteoporosis; Thailand study; bone density.

References

[1] https://finance.yahoo.com/news/press-release-sanofi-teizeild-approved-060000046.html
[2] https://www.koreabiomed.com/news/articleViewAmp.html?idxno=30263
[3] https://www.isct.ac.jp/en/news/sx2binkwhkpc
[4] https://medicaldialogues.in/amp/mdtv/diabetes-endocrinology/videos/groundbreaking-metabolomic-signature-enhances-type-2-diabetes-risk-prediction-model-study-162926
[5] https://medicalxpress.com/news/2026-01-ai-prediabetes-ecg-blood.html
[6] https://www.koreabiomed.com/news/articleView.html?idxno=30331
[7] https://www.marketscreener.com/news/hikma-pharmaceuticals-announces-launch-of-enobya-denosumab-qbde-and-xtrenboa-denosumab-qb-ce7e58dfdf8df621
[8] https://www.geneonline.com/study-in-thailand-finds-higher-osteoporosis-rates-among-type-2-diabetes-patients/